amg-548
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
AMG548 has been shown to inhibit Wnt/ß-catenin signaling which is thought to be due to cross-reactivity with/inhibition of casein kinase Id/¿ (CSNK1D and CSNK1E, PMID:21513885)
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O- Mol. weight
- 461.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL585902 ↗
Also known as
- amg-548
- amg-548